NASDAQ:AIKI AIkido Pharma (AIKI) Stock Price, News & Analysis $5.44 -0.11 (-1.98%) As of 06/30/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About AIkido Pharma Stock (NASDAQ:AIKI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AIkido Pharma alerts:Sign Up Key Stats Today's Range$5.36▼$5.7550-Day Range$4.34▼$6.2552-Week Range$3.31▼$11.48Volume111,073 shsAverage Volume79,326 shsMarket Capitalization$29.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York. Read More Receive AIKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AIKI Stock News HeadlinesAIkido Pharma (NASDAQ:AIKI) Stock Passes Above 200 Day Moving Average - What's Next?June 24, 2025 | americanbankingnews.comDon Jr. And Eric Trump Could Soon Sell $9.6 Million In Stock Granted For Brief Advisory Board Tenure, SEC Filing RevealsApril 26, 2025 | msn.comThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths.July 1 at 2:00 AM | Weiss Ratings (Ad)Don Jr. And Eric Trump Landed $3 Million In Stock For Joining Firm’s Advisory Board That Had Little Public Presence Before Their AppointmentApril 17, 2025 | msn.comTrump Sons Joined Dominari Holding’s Advisory Board–But There’s Little Public Record The Board Existed BeforehandMarch 7, 2025 | forbes.comDon Jr. and Eric Trump invest in small biotech turned fintech based in Trump Tower, sending stock skywardFebruary 12, 2025 | msn.comDominari Holdings Inc trading resumesFebruary 12, 2025 | markets.businessinsider.comSNOA Sonoma Pharmaceuticals, Inc.March 17, 2024 | seekingalpha.comSee More Headlines AIKI Stock Analysis - Frequently Asked Questions How have AIKI shares performed this year? AIkido Pharma's stock was trading at $0.9844 on January 1st, 2025. Since then, AIKI stock has increased by 452.6% and is now trading at $5.44. View the best growth stocks for 2025 here. When did AIkido Pharma's stock split? AIkido Pharma shares reverse split on the morning of Tuesday, June 7th 2022.The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Does AIkido Pharma have any subsidiaries? AIkido Pharma subsidiaries include Hoth Therapeutics. How do I buy shares of AIkido Pharma? Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIkido Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Genetics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and Company Calendar Today7/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:AIKI CIK12239 Webwww.spherix.com Phone(112) 745-1374Fax703-992-9348Employees4Year Founded1967Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-18.21% Return on Assets-16.94% Debt Debt-to-Equity RatioN/A Current Ratio29.54 Quick Ratio29.54 Sales & Book Value Annual Sales$10 thousand Price / Sales2,983.84 Cash FlowN/A Price / Cash FlowN/A Book Value$19.27 per share Price / Book0.28Miscellaneous Outstanding Shares5,485,000Free Float5,013,000Market Cap$29.84 million OptionableNot Optionable Beta0.93 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:AIKI) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIkido Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIkido Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.